20,800 Shares in Anavex Life Sciences Corp. (NASDAQ:AVXL) Purchased by Prairiewood Capital LLC

Prairiewood Capital LLC bought a new stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) in the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 20,800 shares of the biotechnology company’s stock, valued at approximately $223,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of AVXL. JPMorgan Chase & Co. grew its holdings in shares of Anavex Life Sciences by 2.9% in the third quarter. JPMorgan Chase & Co. now owns 42,565 shares of the biotechnology company’s stock valued at $242,000 after purchasing an additional 1,191 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in Anavex Life Sciences by 8.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 30,510 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 2,401 shares during the period. Carnegie Investment Counsel grew its stake in shares of Anavex Life Sciences by 4.7% in the fourth quarter. Carnegie Investment Counsel now owns 76,778 shares of the biotechnology company’s stock worth $825,000 after acquiring an additional 3,445 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Anavex Life Sciences by 6.7% during the third quarter. Franklin Resources Inc. now owns 58,557 shares of the biotechnology company’s stock worth $317,000 after acquiring an additional 3,674 shares during the period. Finally, Private Advisor Group LLC raised its stake in shares of Anavex Life Sciences by 10.3% in the third quarter. Private Advisor Group LLC now owns 47,413 shares of the biotechnology company’s stock valued at $269,000 after acquiring an additional 4,442 shares in the last quarter. 31.55% of the stock is currently owned by hedge funds and other institutional investors.

Anavex Life Sciences Trading Down 9.3 %

Anavex Life Sciences stock opened at $9.21 on Tuesday. The stock has a market cap of $781.19 million, a P/E ratio of -17.71 and a beta of 0.70. The company has a fifty day simple moving average of $9.73 and a 200-day simple moving average of $7.27. Anavex Life Sciences Corp. has a 12-month low of $3.25 and a 12-month high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last released its quarterly earnings data on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.03. As a group, sell-side analysts forecast that Anavex Life Sciences Corp. will post -0.73 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AVXL has been the subject of several analyst reports. HC Wainwright boosted their target price on Anavex Life Sciences from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, December 26th. D. Boral Capital reissued a “buy” rating and set a $46.00 price objective on shares of Anavex Life Sciences in a research report on Monday, January 13th.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.